DCVC Bio founders look for more quick returns, less overhyped AI, with new $400 million fund

DCVC Bio, a Silicon Valley area investment firm launched six years ago by a group of tech, bio, and agriculture investors, has raised a new $400 million fund, it told STAT exclusively.

This is the third fund DCVC Bio has raised. It came in ahead of the original $350 million goal, according to executives.

The announcement makes DCVC Bio one of a select number of biotech VCs to raise new pools of capital this year. Biotech investors raised 53 funds last year and 85 funds in 2022, but halfway through this year, they had raised just 15 funds. (Both ARCH Venture Partners and Flagship Pioneering have announced new fundraisings since then.)

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin – Psychedelic Alpha

This Issue contains three SXSW-inspired musings or updates. The first, and most substantial, looks ahead to just one facet of the potential patient access challenges

March 21, 2024

Stanford Deploys Nuance AI-Powered Clinical Documentation

What You Should Know: – Stanford Health Care, a leader in medical innovation, is deploying Nuance Dragon® Ambient eXperience™ (DAX™) Copilot to streamline clinical documentation

March 11, 2024

Optimind Pharma Announces Entry Into Acquisition Agreement With Wolf Acquisitions | Psychedelic Invest

Optimind Pharma Corp. (CSE: OMND) (the “Optimind” or the “Company”) is pleased to announce that it has entered into an acquisition agreement dated October 12,

October 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.